RxDoctor Payments Data

Mariette Pierre, MD

Internal Medicine · Houston, TXNPI 1972542124

Payments from drug & device makers

$4,730in general payments, 2019–2025

Across 204 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$862
  • Lilly USA, LLC$593
  • Boehringer Ingelheim$457
  • Amgen$292
  • Bayer$275
  • plus $1000 from 15 others

What the payments were for

  • Food & beverage$4,717100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,730 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$29,824
Medicare patients
83
Services billed
305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$122,880
EliquisApixaban65$86,851
MounjaroTirzepatide30$45,877
FarxigaDapagliflozin Propanediol31$36,691
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$36,485
TrulicityDulaglutide19$25,816
LinzessLinaclotide25$23,923
JardianceEmpagliflozin17$22,156
JanuviaSitagliptin Phosphate19$17,359
MyrbetriqMirabegron20$17,017
TradjentaLinagliptin21$16,346
EntrestoSacubitril/Valsartan11$16,059
Wixela InhubFluticasone Propion/Salmeterol12$6,991
Advair HfaFluticasone Propion/Salmeterol18$5,360
Albuterol Sulfate HfaAlbuterol Sulfate136$5,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,252$122,88086 claims
PfizerEliquis$158$86,85165 claims
Lilly USA, LLCMounjaro, Trulicity$593$71,69449 claims
Boehringer IngelheimJardiance, Tradjenta$457$38,50338 claims
AstraZenecaFarxiga$862$36,69131 claims
GSKTrelegy Ellipta$22$36,48529 claims
AbbVieLinzess, Synthroid$125$25,91253 claims
Astellas Pharma US IncMyrbetriq$41$17,01720 claims
NovartisEntresto$37$16,05911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →